|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 216.15 USD | +0.99% |
|
-2.59% | -5.40% |
| 01-20 | Global drugmakers rush to boost US presence as tariff threat looms | RE |
| 01-20 | Berenberg Lifts Price Target on AbbVie to $275 From $270, Keeps Buy Rating | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 45.8B | 56.2B | 58.05B | 54.32B | 56.33B | |||||
Total Revenues | 45.8B | 56.2B | 58.05B | 54.32B | 56.33B | |||||
Cost of Goods Sold, Total | 14.06B | 17.31B | 16.53B | 16.73B | 16.69B | |||||
Gross Profit | 31.75B | 38.88B | 41.53B | 37.59B | 39.64B | |||||
Selling General & Admin Expenses, Total | 9.87B | 11.87B | 12.08B | 12.9B | 13.19B | |||||
R&D Expenses | 6.18B | 6.98B | 6.49B | 7.04B | 8.13B | |||||
Other Operating Expenses | - | 500M | -1M | -10M | -7M | |||||
Other Operating Expenses, Total | 16.05B | 19.35B | 18.57B | 19.93B | 21.31B | |||||
Operating Income | 15.7B | 19.53B | 22.96B | 17.66B | 18.33B | |||||
Interest Expense, Total | -2.45B | -2.42B | -2.23B | -2.22B | -2.81B | |||||
Interest And Investment Income | 174M | 39M | 186M | 540M | 648M | |||||
Net Interest Expenses | -2.28B | -2.38B | -2.04B | -1.68B | -2.16B | |||||
Currency Exchange Gains (Loss) | -71M | -51M | -148M | -146M | -21M | |||||
Other Non Operating Income (Expenses) | 113M | 55M | 142M | 190M | 271M | |||||
EBT, Excl. Unusual Items | 13.46B | 17.15B | 20.91B | 16.02B | 16.42B | |||||
Restructuring Charges | - | - | - | - | - | |||||
Merger & Related Restructuring Charges | -3.11B | -587M | -768M | -119M | -792M | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | 68M | 172M | - | - | |||||
Asset Writedown | - | - | -876M | -4.23B | -4.48B | |||||
In Process R&D Expenses | -1.2B | -962M | -697M | -778M | -2.76B | |||||
Legal Settlements | - | - | -2.5B | 485M | -910M | |||||
Other Unusual Items | -5.75B | -2.68B | -2.76B | -5.13B | -3.77B | |||||
EBT, Incl. Unusual Items | 3.4B | 12.99B | 13.48B | 6.25B | 3.72B | |||||
Income Tax Expense | -1.22B | 1.44B | 1.63B | 1.38B | -570M | |||||
Earnings From Continuing Operations | 4.62B | 11.55B | 11.84B | 4.87B | 4.29B | |||||
Net Income to Company | 4.62B | 11.55B | 11.84B | 4.87B | 4.29B | |||||
Minority Interest | -6M | -7M | -9M | -10M | -8M | |||||
Net Income - (IS) | 4.62B | 11.54B | 11.84B | 4.86B | 4.28B | |||||
Preferred Dividend and Other Adjustments | 60M | 74M | 54M | 43M | 40M | |||||
Net Income to Common Incl Extra Items | 4.56B | 11.47B | 11.78B | 4.82B | 4.24B | |||||
Net Income to Common Excl. Extra Items | 4.56B | 11.47B | 11.78B | 4.82B | 4.24B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.73 | 6.48 | 6.65 | 2.73 | 2.4 | |||||
Basic EPS - Continuing Operations | 2.73 | 6.48 | 6.65 | 2.73 | 2.4 | |||||
Basic Weighted Average Shares Outstanding | 1.67B | 1.77B | 1.77B | 1.77B | 1.77B | |||||
Net EPS - Diluted | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | |||||
Diluted EPS - Continuing Operations | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | |||||
Diluted Weighted Average Shares Outstanding | 1.67B | 1.78B | 1.78B | 1.77B | 1.77B | |||||
Normalized Basic EPS | 5.04 | 6.05 | 7.37 | 5.66 | 5.8 | |||||
Normalized Diluted EPS | 5.03 | 6.03 | 7.34 | 5.64 | 5.78 | |||||
Dividend Per Share | 4.84 | 5.31 | 5.71 | 5.99 | 6.29 | |||||
Payout Ratio | 167.16 | 80.24 | 84.85 | 216.72 | 257.71 | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Supplemental Items | ||||||||||
EBITDA | 22.17B | 28.05B | 31.42B | 26.36B | 26.72B | |||||
EBITA | 21.5B | 27.25B | 30.65B | 25.61B | 25.95B | |||||
EBIT | 15.7B | 19.53B | 22.96B | 17.66B | 18.33B | |||||
EBITDAR | 22.48B | 28.4B | 31.76B | 26.66B | 27.06B | |||||
Effective Tax Rate - (Ratio) | -36.02 | 11.09 | 12.11 | 22.03 | -15.34 | |||||
Current Domestic Taxes | 907M | 1.99B | 2.65B | 3.27B | -331M | |||||
Current Foreign Taxes | 194M | 351M | 916M | 994M | 1.21B | |||||
Total Current Taxes | 1.1B | 2.34B | 3.56B | 4.27B | 879M | |||||
Deferred Domestic Taxes | -58M | -839M | -1.51B | -2.32B | -1.3B | |||||
Deferred Foreign Taxes | -2.27B | -59M | -419M | -565M | -146M | |||||
Total Deferred Taxes | -2.32B | -898M | -1.93B | -2.89B | -1.45B | |||||
Normalized Net Income | 8.41B | 10.71B | 13.06B | 10B | 10.26B | |||||
Interest Capitalized | - | - | - | - | - | |||||
Interest on Long-Term Debt | - | - | - | - | 2.81B | |||||
Non-Cash Pension Expense | -82M | -136M | -182M | -274M | -282M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 1.8B | 2.1B | 2B | 2.2B | 2.1B | |||||
Selling and Marketing Expenses | 1.8B | 2.1B | 2B | 2.2B | 2.1B | |||||
Research And Development Expense From Footnotes | 7.76B | 8.05B | 7.21B | 8.45B | 15.55B | |||||
Net Rental Expense, Total | 311M | 353M | 339M | 305M | 347M | |||||
Imputed Operating Lease Interest Expense | 79.16M | 83.09M | 85.07M | 86.71M | 122M | |||||
Imputed Operating Lease Depreciation | 232M | 270M | 254M | 218M | 225M | |||||
Stock-Based Comp., COGS (Total) | 47M | 46M | 38M | 46M | 91M | |||||
Stock-Based Comp., R&D Exp. (Total) | 247M | 226M | 232M | 278M | 525M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 459M | 420M | 401M | 423M | 805M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 753M | 692M | 671M | 747M | 1.42B |
- Stock Market
- Equities
- ABBV Stock
- Financials AbbVie Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















